Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to key stakeholders, the potential of Poland for Wörwag moving forward, and the significance of the company’s social responsibility towards the medical community and patients.
As the regional manager, how has the experience been thus far and what are your current challenges for the company in the region?
"Our job now is to provide pharmacoeconomic data on the Polish market to the key Polish stakeholders, and in turn this will help in obtaining greater market access of our high-quality treatments."
